Skip to content
Open in App
Alnylam logo

Alnylam

web2

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutic...

Symbol · 1ALNY
Company profile

About

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Launch Alnylam 2030 strategy

KEY STEP

Alnylam formally launched its five year Alnylam 2030 strategy, setting targets for TTR leadership, nucresiran launches, revenue growth, operating margin and pipeline expansion through 2030.

Roadmap reference

First quarterly product revenue above $1 billion

KEY STEP

Alnylam reported first quarter 2026 global net product revenue of $1.036 billion, marking the first time the company exceeded $1 billion of product revenue in a single quarter. Total TTR net product revenue was $910 million, driven primarily by AMVUTTRA.

Roadmap reference

Quarterly TTR product revenue exceeds $1 billion

KEY STEP

Alnylam reported $1.030 billion of total TTR net product revenue in the second quarter of 2026, marking the first quarter in which the TTR franchise exceeded $1 billion of revenue. AMVUTTRA contributed $1.012 billion of the total.

Roadmap reference
People

Company team

CR

Carolyn R. Bertozzi

Member of Scientific Advisory Board

Company leadership profile.

CE

Charles Elliott Sigal

Independent Director

Company leadership profile.

PA

Phillip A. Sharp

Co-Founder, Member of the Scientific Advisory Board

Company leadership profile.

AW

Amy W. Schulman

Independent Chair of the Board

Company leadership profile.

OB

Olivier Brandicourt

Independent Director

Company leadership profile.

YL

Yvonne L. Greenstreet

CEO & Director

Company leadership profile.

MM

Muthiah Manoharan

Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board

Company leadership profile.

DE

David E. I. Pyott

Independent Director

Company leadership profile.

CF

Colleen Foley Reitan

Independent Director

Company leadership profile.

PN

Peter N. Kellogg

Independent Director

Company leadership profile.

PR

Paul R. Schimmel

Member of the Scientific Advisory Board

Company leadership profile.

MS

Markus Stoffel

Member of Scientific Advisory Board

Company leadership profile.

DP

David P. Bartel

Member of Scientific Advisory Board

Company leadership profile.

DA

Dennis Arthur Ausiello

Member of the Scientific Advisory Board & Independent Director

Company leadership profile.

RM

Rachel Meyers

Member of Scientific Advisory Board

Company leadership profile.

DJ

Daniel J. Rader

Member of Scientific Advisory Board

Company leadership profile.

NJ

Nancy J. Brown

Member of Scientific Advisory Board

Company leadership profile.

MA

Margaret A. Hamburg

Independent Director

Company leadership profile.

PS

Priya S. Kishnani

Member of the Scientific Advisory Board

Company leadership profile.

SA

Stuart A. Arbuckle

Independent Director

Company leadership profile.

BF

Benjamin F. Cravatt

Director

Company leadership profile.

Expert coverage

1 expert evaluated Alnylam.

Orbitrum research

Experts evaluating Alnylam

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment